Turtle Cameron 4

What Happened
Turtle Cameron, a director of Damora Therapeutics, was granted a derivative award on 2026-03-23 covering 37,313 shares. The Form 4 reports the acquisition of these derivative securities at $0.00 (no cash paid at grant). This was an award/option grant (not a market purchase or sale).

Key Details

• Transaction date: 2026-03-23; Form 4 filed: 2026-03-25 (within the typical 2-business-day reporting window).
• Transaction type/code: Award/Grant (A) — derivative security representing a right to purchase common stock.
• Amount: 37,313 shares (derivative). Reported price at grant: $0.00 (no upfront payment shown).
• Vesting: Footnote states the option vests in equal monthly installments through March 23, 2029, subject to continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Strike/exercise price: not specified in the excerpted details provided.

Context
This was an option award (a future right to buy shares if and when vested/exercised), common as director compensation. It is not an immediate purchase or sale and does not by itself signal a buy/sell action in the market. If exercised later, it could result in share issuance (dilution) and/or a subsequent sale, but those would be reported separately if they occur.